Expert Review of Anticancer Therapy最新文献_第3页

Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared decision-making. 慢性淋巴细胞白血病（CLL）治疗属性影响患者共同决策的前瞻性患者偏好研究。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-23 DOI: 10.1080/14737140.2026.2722166

Sikander Ailawadhi, Swetha Challagulla, Yan Meng, Todor I Totev, Dominic Pilon, Lilian Diaz, Zhuo Chen, Keri Yang

{"title":"Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared decision-making.","authors":"Sikander Ailawadhi, Swetha Challagulla, Yan Meng, Todor I Totev, Dominic Pilon, Lilian Diaz, Zhuo Chen, Keri Yang","doi":"10.1080/14737140.2026.2722166","DOIUrl":"10.1080/14737140.2026.2722166","url":null,"abstract":"Background: Chronic lymphocytic leukemia (CLL) treatment attributes can impact patient treatment preferences.Research design and methods: A discrete choice experiment survey was conducted among adults with CLL from the United States (12/2024-02/2025). Treatment attributes, selected via literature review and clinical input, spanned across efficacy, safety, and convenience (continuous vs fixed duration with monitoring/hospitalization requirements). Attributes' relative importance was calculated using conditional logistic regression.Results: Among 199 patients with CLL, attributes with the highest relative importance were progression-free survival (PFS; 29.5%), impact of headache, atrial fibrillation, and kidney dysfunction on quality of life (QoL; 25.9%, 24.4%, and 10.1%, respectively), followed by treatment convenience (5.4%) and impacts of diarrhea (3.5%) and hypertension (1.1%) on QoL. Patients preferred treatments with longer PFS and less impact of headache, atrial fibrillation, and kidney dysfunction on QoL (p < 0.001). Impacts of diarrhea and hypertension on QoL and treatment convenience had no statistically significant influence on treatment preferences.Conclusions: PFS, impacts of headache, and atrial fibrillation on QoL were the most important treatment attributes for patients with CLL, whereas treatment convenience did not have a statistically significant impact on patient preferences. CLL treatment discussions should incorporate safety alongside efficacy to support patient-centered care.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":3.0,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors. 核环尼治疗hr阳性/ her2阴性转移性乳腺癌的实际结果：疗效、安全性和预后因素

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-17 DOI: 10.1080/14737140.2026.2733826

Salih Karatlı, Doğan Yazılıtaş, Mustafa Altınbaş

{"title":"Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors.","authors":"Salih Karatlı, Doğan Yazılıtaş, Mustafa Altınbaş","doi":"10.1080/14737140.2026.2733826","DOIUrl":"10.1080/14737140.2026.2733826","url":null,"abstract":"Background: This study evaluated the real-world efficacy, safety, and prognostic factors associated with progression-free survival (PFS) in patients with HR-positive/HER2-negative metastatic breast cancer treated with ribociclib.Research design and methods: This retrospective single-center study included 110 patients treated with ribociclib plus endocrine therapy between January 2023 and January 2026. PFS was estimated using Kaplan-Meier analysis. Prognostic factors were assessed using Cox regression. A 3-month landmark analysis evaluated early dose modification and grade 3-4 neutropenia, and sensitivity analyses assessed model assumptions.Results: Median follow-up was 35.0 months (95% CI: 30.2-39.8), and median PFS for the overall cohort was 31.0 months (95% CI: 24.5-37.5). PFS did not differ significantly between first-line and later-line ribociclib use (p = 0.148). Grade 3-4 neutropenia occurred in 36.4%, and 36.4% required dose modification. In multivariable analysis, each 10-percentage-point increase in Ki-67 was associated with shorter PFS (HR = 1.203; 95% CI: 1.007-1.436; p = 0.041). Neither early dose modification nor early grade 3-4 neutropenia was significantly associated with subsequent PFS.Conclusions: Ribociclib demonstrated clinically meaningful PFS with manageable toxicity in real-world practice. Higher Ki-67 was associated with poorer PFS, although this association was attenuated in sensitivity analysis.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":3.0,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjuvant therapy for resectable gastrointestinal stromal tumors: evidence, controversies, and practical guidance. 可切除胃肠道间质瘤的辅助治疗：证据、争议和实践指导。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-17 DOI: 10.1080/14737140.2026.2733840

Anjali Shah, George John, Anuradha Mehta, Vikas Ostwal, Anant Ramaswamy, Prabhat Bhargava

{"title":"Adjuvant therapy for resectable gastrointestinal stromal tumors: evidence, controversies, and practical guidance.","authors":"Anjali Shah, George John, Anuradha Mehta, Vikas Ostwal, Anant Ramaswamy, Prabhat Bhargava","doi":"10.1080/14737140.2026.2733840","DOIUrl":"https://doi.org/10.1080/14737140.2026.2733840","url":null,"abstract":"Introduction: Surgical resection remains the cornerstone for localized gastrointestinal stromal tumors (GIST), but recurrence risk varies widely. Targeted therapy with imatinib has transformed outcomes in advanced disease and is now used in the adjuvant setting for selected patients.Areas covered: A targeted literature search of PubMed, Embase, major conference abstracts and guidelines documents was conducted up to 1 August 2026. Key evidence on adjuvant imatinib in GIST was reviewed, including randomized trials, prospective cohorts, guidelines, and relevant retrospective studies, with particular focus on treatment benefit, duration, molecular subtypes, and emerging data on extended therapy. Trial data were cross-checked against primary publications and differences in endpoint definitions were harmonized for cross-trial comparison.Expert opinion: Adjuvant imatinib should be individualized using validated clinicopathologic risk models plus molecular testing. Key unresolved issues include optimal duration for the highest-risk subsets, the role and dose of adjuvant therapy for KIT exon 9 tumors, and adjuvant strategies for imatinib-resistant genotypes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study. 机器学习结合可解释的人工智能来预测欧维多汀对尿路上皮癌的毒性：一项探索性研究。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-16 DOI: 10.1080/14737140.2026.2733827

Kannan Sridharan, Mattia Alberto Di Civita, Gowri Sivaramakrishnan, Luca Zacco, Wataru Fukuokaya, Takahiro Kimura, Takafumi Yanagisawa, Jindrich Kopecky, Tarek Taha, Gian Paolo Spinelli, Tomas Buchler, Brigida Anna Maiorano, Andrea Malgeri, Linda Cerbone, Fabio Calabrò, Jawaher Ansari, Se Hoon Park, Aristotelis Bamias, Daniele Santini, Matteo Santoni

{"title":"Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study.","authors":"Kannan Sridharan, Mattia Alberto Di Civita, Gowri Sivaramakrishnan, Luca Zacco, Wataru Fukuokaya, Takahiro Kimura, Takafumi Yanagisawa, Jindrich Kopecky, Tarek Taha, Gian Paolo Spinelli, Tomas Buchler, Brigida Anna Maiorano, Andrea Malgeri, Linda Cerbone, Fabio Calabrò, Jawaher Ansari, Se Hoon Park, Aristotelis Bamias, Daniele Santini, Matteo Santoni","doi":"10.1080/14737140.2026.2733827","DOIUrl":"10.1080/14737140.2026.2733827","url":null,"abstract":"Background: Enfortumab vedotin (EV) therapy for advanced urothelial carcinoma is limited by adverse events (AEs). Early identification of high-risk patients is needed. This proof-of-concept study evaluated whether machine learning (ML) with explainable AI (SHAP) could predict EV toxicities using real-world data.Research design and methods: Data from 542 patients (51 centers, 24 countries) were analyzed. Six outcomes were predicted including grade 3-4 AEs. Four ML algorithms were trained on an 80% split and tested on 20%. Performance was evaluated via standard metrics with SHAP for interpretability.Results: In this exploratory analyses, Random Forest achieved highest overall performance, yielding best AUC for diarrhea, severe AEs, and dose skipping. XGBoost led for cutaneous toxicity and diabetes; LASSO led for neuropathy (differences modest). Age was the most important associated variable, followed by prior immunotherapy and Eastern Cooperative Oncology Group performance status. Liver metastases influenced diabetes and cutaneous toxicity; lung metastases impacted diarrhea, neuropathy, and skin toxicity. SHAP showed atezolizumab/nivolumab linked to lower cutaneous risk, and female sex to higher risk.Conclusion: These preliminary, hypothesis-generating findings suggest ML may predict EV-related toxicities, but single train-test split, small event counts, and lack of external validation preclude clinical use. Prospective validation is essential.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salivary duct carcinoma- contemporary nuts and bolts from pathologist perspective. 涎腺导管癌——从病理学角度看当代的具体情况。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-16 DOI: 10.1080/14737140.2026.2733834

Diana Bell, Renata Ferrarotto, Adel K El-Naggar

{"title":"Salivary duct carcinoma- contemporary nuts and bolts from pathologist perspective.","authors":"Diana Bell, Renata Ferrarotto, Adel K El-Naggar","doi":"10.1080/14737140.2026.2733834","DOIUrl":"10.1080/14737140.2026.2733834","url":null,"abstract":"Introduction: Salivary gland carcinomas are highly heterogeneous malignancies that present a complex variety of histological features and distinct clinical behaviors, with salivary duct carcinoma (SDCa) as the most clinically severe and aggressive subtype. The standard of care for these patients is a combined approach of surgery followed by radiotherapy. The aggressive clinical course of SDCa is primarily driven by frequent disease recurrences and systemic spread.Areas covered: The publication of WHO 5th Classification of Head and Neck tumors has sparked a surge in research targeting SDCa. Owing to the highly aggressive behavior of the tumor, most literature heavily emphasizes the molecular pathology of SDCa.A systematic literature search was conducted using the PubMed with the following search terms: salivary duct carcinoma AND pathology OR updates OR molecular OR signaling pathway OR gene expression OR mutation OR oncogene OR tumor suppressor OR DNA methylation OR tumor microenvironment. Results were limited to primary research articles in English language.Expert opinion: This article outlines key advancements in SDCa morphology, molecular pathology, and targeted therapies. Patient management in precision oncology will be fundamentally transformed by the classification of new morphologic subtypes, the discovery of molecular biomarkers, and an enhanced comprehension of tumor microenvironment.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming emerging challenges in childhood cancer survivorship: a spotlight on pediatric CNS tumors. 克服儿童癌症生存的新挑战：儿童中枢神经系统肿瘤的焦点。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-14 DOI: 10.1080/14737140.2026.2730176

Elisabetta Schiavello, Veronica Biassoni, Olga Nigro, Fabio Simonetti, Alessandro Cattoni, William Zardo, Andrea Trezza, Giorgio Carrabba, Carlo Giussani, Sabina Vennarini, Silvia Esposito, Francesca Filippi, Monica Terenziani, Maura Massimino

{"title":"Overcoming emerging challenges in childhood cancer survivorship: a spotlight on pediatric CNS tumors.","authors":"Elisabetta Schiavello, Veronica Biassoni, Olga Nigro, Fabio Simonetti, Alessandro Cattoni, William Zardo, Andrea Trezza, Giorgio Carrabba, Carlo Giussani, Sabina Vennarini, Silvia Esposito, Francesca Filippi, Monica Terenziani, Maura Massimino","doi":"10.1080/14737140.2026.2730176","DOIUrl":"10.1080/14737140.2026.2730176","url":null,"abstract":"Introduction: Pediatric central nervous system (CNS) tumors are the most common solid malignancies in children. Advances in multimodal therapies have improved survival, resulting in a growing population of long-term survivors who often experience treatment-related morbidity affecting quality of life and functional outcomes. This underscores the importance of comprehensive survivorship care.Areas covered: This review summarizes the multisystem late effects of pediatric CNS tumor treatment, including endocrine dysfunction, fertility impairment, neurocognitive and psychosocial sequelae, second malignant neoplasms, cardiovascular complications, bone health deficits, ototoxicity, and renal, pulmonary, gastrointestinal, and dermatologic toxicities. Emerging survivorship challenges associated with immunotherapy and targeted therapies are also discussed. We further review evidence-based surveillance strategies, interventions to mitigate long-term complications, and current recommendations for risk-adapted follow-up and transition to adult care.Expert opinion: Survivors of pediatric CNS tumors represent one of the highest-risk groups among childhood cancer survivors because of the cumulative burden of endocrine, neurocognitive, cardiometabolic, and psychosocial late effects. Future survivorship care should adopt personalized, multidisciplinary, and risk-stratified approaches, integrating dedicated survivorship clinics, structured transition programs, and long-term monitoring. Improving quality of survival should be prioritized alongside continued gains in survival outcomes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-20"},"PeriodicalIF":3.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of chemotherapy in high-risk gestational trophoblastic neoplasia. 化疗在高危妊娠滋养细胞瘤中的作用。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-10 DOI: 10.1080/14737140.2026.2730174

Antonio Braga, Gabriela Paiva, Manisha Asrani, Jessica St Laurent, Ross Berkowitz, Neil Horowitz

{"title":"The role of chemotherapy in high-risk gestational trophoblastic neoplasia.","authors":"Antonio Braga, Gabriela Paiva, Manisha Asrani, Jessica St Laurent, Ross Berkowitz, Neil Horowitz","doi":"10.1080/14737140.2026.2730174","DOIUrl":"10.1080/14737140.2026.2730174","url":null,"abstract":"Introduction: Gestational trophoblastic neoplasia (GTN) comprises a group of rare malignant disorders arising from placental trophoblastic tissue. Despite the remarkable chemosensitivity of high-risk GTN, delays in diagnosis, inadequate risk stratification, or inappropriate chemotherapy regimens remain the primary determinants of adverse outcomes. Understanding the role of chemotherapy is essential to ensure optimal management, maximize cure rates, and ultimately eliminate preventable mortality associated with this disease.Areas covered: A narrative review of the literature was conducted using PubMed/MEDLINE, Scopus, and Web of Science, from database inception through July 2026, supplemented by manual review of reference lists and international guidelines. Study selection was based on clinical relevance, methodological rigor, and contribution to the understanding of chemotherapy strategies in high-risk disease. The evidence was qualitatively synthesized, focusing on risk stratification, first-line and salvage chemotherapy, treatment outcomes, mechanisms of chemoresistance, emerging therapies, and the management of relapsed disease.Expert opinion: Although multiagent chemotherapy remains the cornerstone of treatment, future advances in molecular diagnostics, predictive biomarkers, targeted therapies, and immunotherapy, together with continued centralization of care, have the potential to further personalize treatment, reduce toxicity, and improve outcomes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":3.0,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fertility preservation in women with central nervous system tumors. 中枢神经系统肿瘤患者的生育能力保存。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-09 DOI: 10.1080/14737140.2026.2731197

Alicia Tosoni, Chiara Gorbi, Maurizio Mascarin, Elisa Coassin, Diego Raimondo, Marisol Doglioli, Rossella Vicenti, Vincenzo Di Nunno, Lidia Gatto, Stefania Bartolini, Renato Seracchioli, Enrico Franceschi

{"title":"Fertility preservation in women with central nervous system tumors.","authors":"Alicia Tosoni, Chiara Gorbi, Maurizio Mascarin, Elisa Coassin, Diego Raimondo, Marisol Doglioli, Rossella Vicenti, Vincenzo Di Nunno, Lidia Gatto, Stefania Bartolini, Renato Seracchioli, Enrico Franceschi","doi":"10.1080/14737140.2026.2731197","DOIUrl":"10.1080/14737140.2026.2731197","url":null,"abstract":"Introduction: Fertility preservation is an increasingly important component of survivorship care for adolescent and young adult (AYA) women with central nervous system (CNS) tumors. As survival improves, attention to long-term reproductive health is increasingly needed.Areas covered: This narrative review examines how CNS tumors and their treatments may impair fertility, including hypothalamic-pituitary dysfunction, spinal irradiation, and chemotherapy-induced ovarian toxicity, particularly from alkylating agents. Established fertility preservation strategies, including oocyte and embryo cryopreservation, and emerging approaches are discussed, together with the limited evidence on the reproductive effects of newer neuro-oncology therapies and the management of pregnancy after CNS tumor diagnosis. A PubMed search of literature published up to March 2026 was performed, including prospective and retrospective studies, systematic reviews, meta-analyses, clinical guidelines, and relevant case reports addressing fertility preservation and pregnancy in women with CNS tumors.Expert opinion: Early oncofertility counseling and individualized fertility risk assessment should be integrated into routine neuro-oncology care before potentially gonadotoxic treatments. Multidisciplinary management and long-term reproductive follow-up are essential to support informed reproductive decisions, while prospective studies are needed to clarify the reproductive effects of newer therapies and the impact of pregnancy on CNS tumor behavior.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":3.0,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulatory and scientific challenges in pediatric oncology. 儿科肿瘤学的监管和科学挑战。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-09 DOI: 10.1080/14737140.2026.2730175

Stefania Bellino, Daniela Lucente, Anna La Salvia

{"title":"Regulatory and scientific challenges in pediatric oncology.","authors":"Stefania Bellino, Daniela Lucente, Anna La Salvia","doi":"10.1080/14737140.2026.2730175","DOIUrl":"10.1080/14737140.2026.2730175","url":null,"abstract":"Introduction: Pediatric oncology poses distinct scientific, ethical, regulatory, and commercial challenges compared to adult oncology. Although survival rates for certain childhood malignancies have improved significantly, progress in relapsed, refractory, and rare pediatric cancers remains limited.Areas covered: A comprehensive literature search was performed using major biomedical databases, including PubMed, Scopus, and Web of Science. Historically, pediatric drug development followed adult approvals, resulting in significant delays in access to innovative therapies. Recent pediatric regulatory reforms have shifted requirements from indication-based approaches toward mechanism-of-action-based evaluation, promoting earlier and more biologically relevant pediatric investigation. This report examines the biological differences between pediatric and adult cancer populations, reviews the evolution of pediatric oncology from a regulatory perspective, identifies the principal scientific and operational barriers limiting progress, and outlines strategic pathways to accelerate the development of safe and effective therapies for children with cancer.Expert opinion: Despite meaningful therapeutic advances, pediatric oncology drug development remains constrained by small patient populations, biological divergence from adult malignancies, long-term safety considerations, and limited commercial incentives. Overcoming these challenges will require global collaboration, regulatory alignment, innovative trial design, and a deliberate focus on child-specific tumor biology rather than extrapolating from adult oncology paradigms.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148896872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Key barriers in utilizing advanced T-cell engager strategies on solid tumors. 利用先进的t细胞接合器策略治疗实体瘤的关键障碍。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-07 DOI: 10.1080/14737140.2026.2730177

Bo Mi Ku, Sung-Won Lim, Jieun Uhm, Byeong-Bae Park, Myung-Ju Ahn

{"title":"Key barriers in utilizing advanced T-cell engager strategies on solid tumors.","authors":"Bo Mi Ku, Sung-Won Lim, Jieun Uhm, Byeong-Bae Park, Myung-Ju Ahn","doi":"10.1080/14737140.2026.2730177","DOIUrl":"10.1080/14737140.2026.2730177","url":null,"abstract":"Introduction: T cell engagers (TCEs) are engineered immune-mobilizing molecules that recruit T cells toward tumor cells. TCEs have demonstrated clinical efficacy in hematologic malignancies and currently show therapeutic potential in solid tumors through the approvals of tebentafusp and tarlatamab in uveal melanoma and small cell lung cancer. However, implementation of TCEs in solid tumors presents distinct challenges owing to tumor intrinsic features such as lack of specific antigens, biochemical and physical barriers that hinder T cell infiltration, complex immunosuppressive microenvironments, and intrinsic or acquired resistance to TCEs.Areas covered: This review aims to cover inclusive overview of the current portrait of TCEs for the treatment of solid tumors. It provides the mechanisms and design principle of TCE and addresses the challenges that impede treatment efficacy. Especially, we extensively depict the primary and acquired resistance mechanisms to TCEs. Moreover, we highlight the next-generation directions such as engineering of antibody format and combination strategies to overcome these challenges and improve the clinical efficacy.Expert opinion: Integrating logical target selection, advanced engineering, biomarker-guided patient stratification, and deliberate clinical design allows TCEs to successfully expand the reach of novel immunotherapeutics into solid tumors.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-17"},"PeriodicalIF":3.0,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0